Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ACTU
stocks logo

ACTU

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker
Wall Street analysts forecast ACTU stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACTU is 21.67 USD with a low forecast of 20.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast ACTU stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACTU is 21.67 USD with a low forecast of 20.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.350
sliders
Low
20.00
Averages
21.67
High
25.00
Current: 7.350
sliders
Low
20.00
Averages
21.67
High
25.00
B. Riley
NULL -> Buy
initiated
$20
2025-08-26
Reason
B. Riley
Price Target
$20
2025-08-26
initiated
NULL -> Buy
Reason
B. Riley initiated coverage of Actuate Therapeutics with a Buy rating and $20 price target. The firm views the company's lead asset elraglusib as a "transformative" advancement in pancreatic ductal adenocarcinoma treatment. In a Phase 2 study, elraglusib delivered an "unprecedented" survival benefit in the front-line setting with a 37% reduction in death risk that remained consistent in more aggressive disease characterized by the presence of liver metastasis, the analyst tells investors in a research note.
HC Wainwright & Co.
Swayampakula Ramakanth
Strong Buy
Initiates
$20
2025-03-17
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Price Target
$20
2025-03-17
Initiates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Actuate Therapeutics Inc (ACTU.O) is 0.00, compared to its 5-year average forward P/E of -0.09. For a more detailed relative valuation and DCF analysis to assess Actuate Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-0.09
Current PE
0.00
Overvalued PE
0.66
Undervalued PE
-0.84

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

ACTU News & Events

Events Timeline

(ET)
2025-09-22
08:47:42
Actuate Provides Corporate Update on Regulatory Progress for Elraglusib
select
2025-09-10 (ET)
2025-09-10
08:42:12
Actuate sets price for 2.14 million shares at $7.00 in public offering with underwriters
select
2025-09-10
08:34:46
Actuate Therapeutics Sets Secondary Offering of 2.142 Million Shares at $7.00 Each
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
09-23Benzinga
HC Wainwright & Co. Affirms Buy Rating for Actuate Therapeutics, Keeps $20 Price Target Intact

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make winning trades in the stock market.

  • Exclusive Community: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.

[object Object]
Preview
8.5
09-10Newsfilter
Actuate Therapeutics Reveals Pricing for $15.0 Million Public Stock Offering

  • Public Offering Announcement: Actuate Therapeutics, Inc. has priced an underwritten public offering of 2,142,858 shares of common stock at $7.00 per share, aiming to raise approximately $15 million for working capital and corporate purposes.

  • Use of Proceeds: The company plans to utilize the net proceeds from the offering for general corporate needs, with the offering expected to close on September 11, 2025, pending customary closing conditions.

  • Company Focus: Actuate Therapeutics is a clinical-stage biopharmaceutical company developing therapies for challenging cancers, with its lead drug, elraglusib, targeting pathways that promote tumor growth and resistance to conventional treatments.

  • Forward-Looking Statements: The press release includes forward-looking statements regarding the offering's timing and completion, emphasizing the inherent risks and uncertainties that could affect actual results.

[object Object]
Preview
4.0
08-26Benzinga
Actuate Therapeutics Analyst Starts Coverage Positively; Check Out Tuesday's Top 3 Initiations

  • Analyst Ratings Updates: Top Wall Street analysts have revised their outlooks on several companies, with a focus on upgrades and new coverage initiations.

  • Actuate Therapeutics Coverage: B. Riley Securities analyst Mayank Mamtani initiated coverage on Actuate Therapeutics (ACTU) with a Buy rating and a price target of $20, while the stock closed at $7.98.

  • Gyre Therapeutics Coverage: HC Wainwright & Co. analyst Matthew Keller also initiated coverage on Gyre Therapeutics (GYRE) with a Buy rating and a price target of $18, closing at $8.18.

  • CareDx Coverage: William Blair analyst Andrew Brackmann started coverage on CareDx (CDNA) with a Market Perform rating, with shares closing at $12.75.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Actuate Therapeutics Inc (ACTU) stock price today?

The current price of ACTU is 7.35 USD — it has decreased -1.08 % in the last trading day.

arrow icon

What is Actuate Therapeutics Inc (ACTU)'s business?

Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). The Company is developing elraglusib, a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3b, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, which lead to tumor cell survival, growth, migration, and invasion. Its candidate products are Elraglusib Injection and Elraglusib Oral Tablet. Elraglusib is the lead drug in the portfolio and is being evaluated in a randomized Phase II trial in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Elraglusib is designed to act as a mediator of antitumor immunity through the inhibition of NF-kB and regulates multiple immune checkpoints and immune cell function.

arrow icon

What is the price predicton of ACTU Stock?

Wall Street analysts forecast ACTU stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACTU is 21.67 USD with a low forecast of 20.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Actuate Therapeutics Inc (ACTU)'s revenue for the last quarter?

Actuate Therapeutics Inc revenue for the last quarter amounts to -5.47M USD, increased 1.47 % YoY.

arrow icon

What is Actuate Therapeutics Inc (ACTU)'s earnings per share (EPS) for the last quarter?

Actuate Therapeutics Inc. EPS for the last quarter amounts to USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for Actuate Therapeutics Inc (ACTU)'s fundamentals?

The market is revising No Change the revenue expectations for Actuate Therapeutics, Inc. (ACTU) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -10.80%.
arrow icon

How many employees does Actuate Therapeutics Inc (ACTU). have?

Actuate Therapeutics Inc (ACTU) has 10 emplpoyees as of December 05 2025.

arrow icon

What is Actuate Therapeutics Inc (ACTU) market cap?

Today ACTU has the market capitalization of 170.84M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free